ProCE Banner Activity

Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations: TROPION-Pan Tumor01 Phase I Trial Subset Analysis

Slideset Download
Conference Coverage
In this phase I study subset analysis, datopotamab deruxtecan demonstrated antitumor activity and manageable toxicity in patients with heavily pretreated advanced NSCLC with actionable genomic alterations.

Released: September 30, 2021

Expiration: September 29, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc